​​​​​Risk Factors
​​​​Did You Know?

Male Breast Cancer Study Male Breast Cancer Clinical Trial

       Did You Know?

Innocrin Pharmaceuticals' clinical study INO-VT-464-CL-006 is evaluating the safety, tolerability, pharmacokinetics and activity of seviteronel (VT-464), 
a lyase-selective inhibitor of CYP17 and androgen receptor antagonist,
in men with advanced breast cancer.

Male Breast Cancer Study Breast Cancer Clinical Trial

You can add HTML directly into this element to render on the page.

Just edit this element to add your own HTML.

Innocrin Pharmaceutics, Inc.
4505 Emperor Blvd Suite 315
Durham NC 27703


About 2,000 men are diagnosed

with breast cancer each year.


To the Clarity Male Breast Cancer Study Information Page

To learn more about the study, call 1-800-713-6818

Treatment option for male breast cancer

​​The Male Breast Cancer study is currently enrolling patients across the U.S. Contact us today to find a participating clinic near you.

A number of factors can increase a man's risk of getting breast cancer including but not limited to:

  • Family history of breast cancer
  • Prior estrogen therapy
  • Age
  • Breast enlargement or sensitivity